Related Experiment Video
Updated: Mar 2, 2026
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Once-daily rivaroxaban for long-term stroke prevention in patients with atrial fibrillation
Sotiris Antoniou1, Walid Amara2
1Cardiovascular Medicine, Barts Health NHS Trust, St Bartholomew's Hospital, West Smithfield, London EC1A 7BE, UK.
Insights
For patients with atrial fibrillation (AF), rivaroxaban offers an effective oral anticoagulation option to prevent stroke. Its once-daily dosing and established safety profile support adherence and improved patient outcomes.
Area of Science:
- Cardiology
- Pharmacology
- Internal Medicine
Background:
- Oral anticoagulation is standard for stroke prevention in atrial fibrillation (AF).
- Anticoagulation carries bleeding risks, necessitating careful benefit-risk assessment.
- Non-vitamin K antagonist oral anticoagulants (NOACs) are alternatives to warfarin.
Purpose of the Study:
- To evaluate rivaroxaban as an alternative to vitamin K antagonists for stroke prevention in AF.
- To highlight the efficacy and safety of rivaroxaban in diverse patient populations.
- To emphasize the advantages of fixed-dose, once-daily administration.
Main Methods:
- Review of Phase III studies on rivaroxaban in non-valvular AF.
- Analysis of safety and efficacy data, including in elderly patients and those with comorbidities.
- Assessment of dosing convenience and patient adherence factors.
Main Results:
- Rivaroxaban is supported by guidelines as optimal for moderate-to-high risk AF patients.
- Phase III studies confirm rivaroxaban's safety and efficacy.
- Once-daily dosing enhances medication adherence.
Conclusions:
- Rivaroxaban provides an effective and safe oral anticoagulation option for non-valvular AF.
- Fixed-dose, once-daily rivaroxaban may improve patient outcomes and adherence.
- The benefit-risk profile supports rivaroxaban use in AF patients at risk of stroke.
Abstract:
Oral anticoagulation is the long-term standard of care for preventing stroke in patients with atrial fibrillation (AF). However, anticoagulation is associated with an increased risk of bleeding, such that its use should be based on the absolute risks of stroke and bleeding, and the relative benefit-risk profile of the individual patient. Non-vitamin K antagonist oral anticoagulants, including rivaroxaban, are alternatives to vitamin K antagonists such as warfarin in this setting, and are supported in treatment guidelines as the optimal choice for patients with AF at moderate to high risk of stroke. Rivaroxaban can be given in fixed doses without routine coagulation monitoring, and phase III studies have demonstrated its safety profile and efficacy in patients with non-valvular AF, including the elderly and those with co-morbidities. Moreover, rivaroxaban is administered once daily, which has advantages for optimal patient adherence to medication over the long term. The established efficacy and safety profile of rivaroxaban, together with its convenient once-daily dosing schedule, may contribute to improved patient outcomes and lead to sustained benefits for patients with non-valvular AF at risk of stroke.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:26Atherosclerosis III: Management
01:30Venous Thrombosis IV: Nursing Management
01:26Coronary Artery Disease IV: Preventive Measures